Department of Immunization, Huangpu District Center for Disease Control and Prevention, Shanghai, China.
Department ofImmunization and Epidemiology, Xuhui District Center for Disease Control and Prevention, Shanghai, China.
Hum Vaccin Immunother. 2021 May 4;17(5):1382-1386. doi: 10.1080/21645515.2020.1819102. Epub 2020 Oct 20.
Disseminated bacillus Calmette-Guérin (BCG) disease is a rare and serious adverse event following immunization (AEFI) with BCG. Here, we reported two cases of disseminated BCG disease in the same family and reviewed the literature to identify another 35 cases in China. The average age at onset was 3.7 ± 2.1 months among the 37 cases and only 21 cases (56.8%) were laboratory confirmed. Of the 37 cases, 22 were evaluated for immunodeficiency; definite immunodeficiency was observed in 16 cases (72.7%) and could not be excluded in the other six cases (27.3%). Following treatment, 20 of the 37 cases died (54.1%), one case developed sequelae (2.7%), four cases had progressive disease (10.8%), nine cases had stable disease (24.3%), and only three cases were cured (8.1%). Vaccination of infants with BCG is cost-effective and should not be stopped because of the possibility of rare disseminated BCG disease, especially in countries with high tuberculosis burdens such as China. However, infants with a family history of immunodeficiency should be vaccinated after excluding immunodeficiency-related diseases to minimize the risk of disseminated BCG disease. Furthermore, government should strengthen proactive surveillance programs to detect and treat rare AEFIs early and improve disease outcomes.
卡介苗(BCG)播散性疾病是一种罕见且严重的接种卡介苗后不良反应(AEFI)。在此,我们报告了同一家庭中两例播散性 BCG 疾病病例,并对中国的另外 35 例病例进行了文献回顾。37 例患者的平均发病年龄为 3.7±2.1 个月,仅有 21 例(56.8%)经实验室确诊。在 37 例患者中,有 22 例进行了免疫缺陷评估;16 例(72.7%)观察到明确的免疫缺陷,6 例(27.3%)不能排除免疫缺陷。经过治疗,37 例患者中 20 例死亡(54.1%),1 例发生后遗症(2.7%),4 例病情进展(10.8%),9 例病情稳定(24.3%),仅有 3 例治愈(8.1%)。接种卡介苗对婴儿是具有成本效益的,不应因为存在罕见的播散性 BCG 疾病的可能性而停止接种,特别是在中国这样的结核病负担较高的国家。然而,有免疫缺陷家族史的婴儿应在排除免疫缺陷相关疾病后接种疫苗,以最大限度地降低播散性 BCG 疾病的风险。此外,政府应加强主动监测计划,以早期发现和治疗罕见的 AEFI,并改善疾病结局。